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This special issue is devoted to revisit the “amyloid cas-
cade hypothesis” (ACH) in the pathogenesis of sporadic
Alzheimer’s disease (AD). Since the identification 20 years
ago of the first APP mutation [1] the ACH gained enormous
importance based on genetic and biochemical evidence.
However the outcome of recent clinical trials aimed at reduc-
ing extracellular Aβ levels suggests that such strategy may
not have the expected impact on AD progression because
the role of Aβ is more complex than that of the lone driver
of AD. Some of the reasons proposed for the failure may
be the initiation of the trials in demented patients with
serious brain damage, and unforeseen serious design flaws
in the studies. These results led us to ask whether Aβ plays
an active protective role in brain aging. It is also clear that
regardless of whether Aβ is protective or toxic, trials focused
on modulating the Aβ response will remain a major interest
in AD therapeutic research.
According to the amyloid cascade hypothesis, increased
amounts of Aβ contribute to the development of AD [2]. Aβ
peptides are generated in the amyloidogenic pathway of APP
processing by sequential proteolysis by β- and γ-secretases. In
the alternative nonamyloidogenic APP processing pathway,
α-secretase cleaves within the Aβ peptide region and prevents
Aβ generation. Increasing the α-secretase-mediated process-
ing of APP may therefore be a therapeutic option for the
treatment of AD. Since various substrates have been assigned
to α-secretase-like cleavage events, putative side eﬀects of
α-secretase activators should be considered. BACE1, the
catalytic component of β-secretase, is the key enzyme initi-
ating Aβ production in vivo, making it a prime drug target
for AD treatment. The past decade has shown significant
progress in the understanding of BACE1 molecular and
cellular properties, however, further investigation is crucial
to predict side eﬀects of BACE1 inhibition. γ-Secretase
complex represents a fascinating biological machine that is
assembled from at least four core proteins (presenilins 1 or
2, APH1, PEN2, and nicastrin). These proteins are suﬃcient
for cleavage of multiple diﬀerent, nonhomologous type 1
transmembrane (TM) proteins, with the cleavage occurring
through the substrates’ TM domains. γ-Secretase remains a
target of intense interest for modulating Aβ. Nowadays, the
focus has clearly shifted toward modulators that minimize
eﬀects on other substrates (in particular notch), with
compounds that either shift the site of cleavage to produce
shorter forms of Aβ or selectively inhibit APP processing
while allowing the enzyme to continue processing notch.
Compounds now under investigationmay not have suﬃcient
potency, brain penetration, or selectivity to eﬀectively lower
brain Aβ while avoiding notch-related toxicity. Recently,
another secretase-mediated APP-derived catabolite called
APP Intra Cellular Domain (AICD) gained relevance in the
field appears to be a multifunctional factor aﬀecting several
physiological processes likely to contribute to Alzheimer’s
disease pathology by acting as a transcription factor that
controls the expression of a series of proteins involved in
control of cell death and Aβ degradation.
The steady state of monomeric Aβ in the brain is the
result of a tightly controlled balance between production
and removal; sporadic AD may reflect defects in clearance
mechanisms for Aβ rather than in the enhanced synthesis
which occurs in early-onset cases. It was recently demon-
strated that the kinetics of Aβ production is similar between
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control and late-onset AD patients, however there is an
impairment in the clearance of Aβ in AD as compared to
controls, indicating that Aβ clearance mechanisms may be
critically important in AD [3]. Among these mechanisms,
interaction of Aβ with ApoE, decreased catabolism via
reduced proteolysis, impaired transport across the blood-
brain barrier, and impaired CSF transport deserve special
attention. Based on experimental evidence in animal models
of AD, upregulation of amyloid degrading enzymes (ADEs)
individually in the brain appears to be a viable strategy to
reduce the amyloid burden and improve cognitive function.
However, these animal models in themselves have limitations
to representing the human disease.
With evidence that the extent of insoluble, deposited
amyloid poorly correlated with cognitive impairment, re-
search eﬀorts focused on soluble forms of Aβ, also referred
to as Aβ oligomers. Following a decade of studies, soluble
oligomeric forms of Aβ are now believed to be the most
biologically active form of Aβ. Understanding the events trig-
gered by oligomeric Aβ species has greatly improved in the
past years but specific eﬀorts are required to understand
the molecular mechanism(s) of endogenous Aβ assemblies.
Brain amyloid deposits contain proteins besides Aβ, such
as apolipoprotein E (apoE). Significantly, inheritance of the
apoE4 allele is the strongest genetic risk factor for the
most common, late-onset form of AD. However, there is
no consensus on how diﬀerent apoE isotypes contribute to
AD pathogenesis. It has been hypothesized that apoE4 in
particular is an amyloid catalyst or “pathological chaperone”.
Evidence from numerous epidemiological studies indicates
that type 2 diabetes, a non-insulin-dependent form of
diabetes mellitus, is associated with a 2- to 3-fold increase
in the relative risk for sporadic AD. Experimental evidence
suggests that abnormalities in insulin metabolism in diabetic
conditions could mechanistically influence the onset of AD
via modulation of the synthesis and degradation of amy-
loidogenic Aβ peptides, providing a molecular link between
metabolic dysfunction and neurodegenerative process in the
elder population.
In this special issue D. A. Bo´rquez and C. Gonza´lez-
Billault review the potential role of multiprotein complexes
between the AICD and its adapter protein Fe65 and how
these complexes impact on the neurodegeneration observed
in AD. G. M. Pasinetti and colleagues describe the role
of insulin receptor (IR) signaling mechanisms in the onset
and/or progression of AD dementia and the relevance of
insulin-sensitizing therapeutic strategies to stimulate down-
stream IR in nondiabetic AD patients. C. Reitz critically
reviews the evidence for and against the amyloid cascade
hypothesis in AD and provides suggestions for future
directions. T. Wisniewski and Huntington Potter consider
the scientific basis of the contrasting views of apoE’s role,
suggesting that these seemingly opposing views can be
reconciled. A. J. Turner and colleagues critically evaluate gen-
eral biochemical and physiological functions of Neprilysin,
one of the relevant ADEs in the human brain, and their
therapeutic relevance.
We hope that this focused series of articles will provide
the readers a critical overview of current understanding of





[1] A. Goate, M. C. Chartier-Harlin, M. Mullan et al., “Segregation
of a missense mutation in the amyloid precursor protein gene
with familial Alzheimer’s disease,” Nature, vol. 349, no. 6311,
pp. 704–706, 1991.
[2] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheim-
er’s disease: progress and problems on the road to therapeutics,”
Science, vol. 297, no. 5580, pp. 353–356, 2002.
[3] K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., “Decreased
clearance of CNS β-amyloid in Alzheimer’s disease,” Science,
vol. 330, no. 6012, p. 1774, 2010.
